id stringlengths 51 101 | query_id stringclasses 37
values | disease stringclasses 8
values | Patient stringclasses 181
values | doc_id stringclasses 298
values | Label stringclasses 3
values | title stringclasses 298
values | Title stringclasses 298
values | Summary stringlengths 46 4.77k | Detailed_description stringlengths 0 18.6k | Eligibility stringlengths 23 10.8k | original_id int64 100 33.8k | source_id stringclasses 300
values | Source_Label stringclasses 3
values | task stringclasses 1
value | augmentation dict |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
araag2/TREC_Clinical-Trials:2023_processed:test:100 | 1 | glaucoma | definitive diagnosis: primary open angle glaucoma
visual field: moderate field damage
visual acuity: 0.3
prior cataract surgery: no
prior LASIK surgery: no
comorbid ocular diseases: corneal edema | NCT00327613 | possibly relevant | Plasma Levels of Matrix Metalloproteinases (MMPs) and Degree of DNA Fragmentation in Pseudoexfoliation (PEX) Glaucoma | Plasma Levels of Matrix Metalloproteinases (MMPs) and Degree of DNA Fragmentation in Pseudoexfoliation (PEX) Glaucoma | Glaucoma is a worldwide leading cause of blindness. The key feature of this ocular neuropathy
is characterized by an excavating optic nerve head. Loss of retinal ganglion cells is the
final end point in blinding diseases of the optic nerve such as glaucoma. It is known that
neuronal cell death in glaucoma occurs by ... | Hypothesis:
Subjects with pseudoexfoliation syndrome in combination with glaucoma may have an altered
activity of plasma matrix-metalloproteinase activity and a higher degree of DNA fragmentation
in the leukocytes.
Specific aims:
Determination of the level of plasma matrix-metalloproteinase activity and of t... | Inclusion Criteria:
- German native speakers
- Age between 18-80 years
- Pseudoexfoliation syndrome
- Pseudoexfoliation syndrome with open-angle glaucoma
- Primary open-angle glaucoma
Exclusion Criteria:
- Any history of ocular or systemic diseases other than glaucoma or of drug or alcohol
a... | 100 | araag2/TREC_Clinical-Trials:2023_processed:test:100 | possibly relevant | document_relevance | {
"candidate": null,
"changes": null,
"effect": null,
"intent": null,
"label_status": null,
"mode": "original",
"side": null,
"summary": null,
"variant": null
} |
araag2/TREC_Clinical-Trials:2023_processed:test:100__aug_patient_restructure_note_1 | 1 | glaucoma | Current findings include a visual acuity of 0.3, moderate field damage on visual field testing, and comorbid corneal edema. The patient has a definitive diagnosis of primary open angle glaucoma and no history of LASIK surgery or cataract surgery. | NCT00327613 | possibly relevant | Plasma Levels of Matrix Metalloproteinases (MMPs) and Degree of DNA Fragmentation in Pseudoexfoliation (PEX) Glaucoma | Plasma Levels of Matrix Metalloproteinases (MMPs) and Degree of DNA Fragmentation in Pseudoexfoliation (PEX) Glaucoma | Glaucoma is a worldwide leading cause of blindness. The key feature of this ocular neuropathy
is characterized by an excavating optic nerve head. Loss of retinal ganglion cells is the
final end point in blinding diseases of the optic nerve such as glaucoma. It is known that
neuronal cell death in glaucoma occurs by ... | Hypothesis:
Subjects with pseudoexfoliation syndrome in combination with glaucoma may have an altered
activity of plasma matrix-metalloproteinase activity and a higher degree of DNA fragmentation
in the leukocytes.
Specific aims:
Determination of the level of plasma matrix-metalloproteinase activity and of t... | Inclusion Criteria:
- German native speakers
- Age between 18-80 years
- Pseudoexfoliation syndrome
- Pseudoexfoliation syndrome with open-angle glaucoma
- Primary open-angle glaucoma
Exclusion Criteria:
- Any history of ocular or systemic diseases other than glaucoma or of drug or alcohol
a... | 100 | araag2/TREC_Clinical-Trials:2023_processed:test:100 | possibly relevant | document_relevance | {
"candidate": "araag2/TREC_Clinical-Trials:2023_processed:test:patient:1__restructure_note_1",
"changes": {
"edited": [
"PT"
],
"order": null
},
"effect": "preserving",
"intent": "preserving",
"label_status": "source_label_presumed_invariant",
"mode": "restructure_note",
"side": "pati... |
araag2/TREC_Clinical-Trials:2023_processed:test:100__aug_patient_restructure_note_7 | 1 | glaucoma | Diagnosis: primary open angle glaucoma. Comorbidities include corneal edema. Visual acuity is 0.3, and the visual field shows moderate damage. History is negative for cataract and LASIK surgery. | NCT00327613 | possibly relevant | Plasma Levels of Matrix Metalloproteinases (MMPs) and Degree of DNA Fragmentation in Pseudoexfoliation (PEX) Glaucoma | Plasma Levels of Matrix Metalloproteinases (MMPs) and Degree of DNA Fragmentation in Pseudoexfoliation (PEX) Glaucoma | Glaucoma is a worldwide leading cause of blindness. The key feature of this ocular neuropathy
is characterized by an excavating optic nerve head. Loss of retinal ganglion cells is the
final end point in blinding diseases of the optic nerve such as glaucoma. It is known that
neuronal cell death in glaucoma occurs by ... | Hypothesis:
Subjects with pseudoexfoliation syndrome in combination with glaucoma may have an altered
activity of plasma matrix-metalloproteinase activity and a higher degree of DNA fragmentation
in the leukocytes.
Specific aims:
Determination of the level of plasma matrix-metalloproteinase activity and of t... | Inclusion Criteria:
- German native speakers
- Age between 18-80 years
- Pseudoexfoliation syndrome
- Pseudoexfoliation syndrome with open-angle glaucoma
- Primary open-angle glaucoma
Exclusion Criteria:
- Any history of ocular or systemic diseases other than glaucoma or of drug or alcohol
a... | 100 | araag2/TREC_Clinical-Trials:2023_processed:test:100 | possibly relevant | document_relevance | {
"candidate": "araag2/TREC_Clinical-Trials:2023_processed:test:patient:1__restructure_note_7",
"changes": {
"edited": [
"PT"
],
"order": null
},
"effect": "preserving",
"intent": "preserving",
"label_status": "source_label_presumed_invariant",
"mode": "restructure_note",
"side": "pati... |
araag2/TREC_Clinical-Trials:2023_processed:test:100__aug_patient_restructure_note_8 | 1 | glaucoma | The patient has primary open angle glaucoma. Visual field damage is moderate. Visual acuity is 0.3. The patient has not had cataract surgery. LASIK surgery was not performed. Corneal edema is a comorbid ocular disease. | NCT00327613 | possibly relevant | Plasma Levels of Matrix Metalloproteinases (MMPs) and Degree of DNA Fragmentation in Pseudoexfoliation (PEX) Glaucoma | Plasma Levels of Matrix Metalloproteinases (MMPs) and Degree of DNA Fragmentation in Pseudoexfoliation (PEX) Glaucoma | Glaucoma is a worldwide leading cause of blindness. The key feature of this ocular neuropathy
is characterized by an excavating optic nerve head. Loss of retinal ganglion cells is the
final end point in blinding diseases of the optic nerve such as glaucoma. It is known that
neuronal cell death in glaucoma occurs by ... | Hypothesis:
Subjects with pseudoexfoliation syndrome in combination with glaucoma may have an altered
activity of plasma matrix-metalloproteinase activity and a higher degree of DNA fragmentation
in the leukocytes.
Specific aims:
Determination of the level of plasma matrix-metalloproteinase activity and of t... | Inclusion Criteria:
- German native speakers
- Age between 18-80 years
- Pseudoexfoliation syndrome
- Pseudoexfoliation syndrome with open-angle glaucoma
- Primary open-angle glaucoma
Exclusion Criteria:
- Any history of ocular or systemic diseases other than glaucoma or of drug or alcohol
a... | 100 | araag2/TREC_Clinical-Trials:2023_processed:test:100 | possibly relevant | document_relevance | {
"candidate": "araag2/TREC_Clinical-Trials:2023_processed:test:patient:1__restructure_note_8",
"changes": {
"edited": [
"PT"
],
"order": null
},
"effect": "preserving",
"intent": "preserving",
"label_status": "source_label_presumed_invariant",
"mode": "restructure_note",
"side": "pati... |
araag2/TREC_Clinical-Trials:2023_processed:test:100__aug_patient_restructure_note_2 | 1 | glaucoma | Dx: primary open angle glaucoma. Moderate visual field damage. VA 0.3. No history of cataract or LASIK surgery. Comorbid corneal edema. | NCT00327613 | possibly relevant | Plasma Levels of Matrix Metalloproteinases (MMPs) and Degree of DNA Fragmentation in Pseudoexfoliation (PEX) Glaucoma | Plasma Levels of Matrix Metalloproteinases (MMPs) and Degree of DNA Fragmentation in Pseudoexfoliation (PEX) Glaucoma | Glaucoma is a worldwide leading cause of blindness. The key feature of this ocular neuropathy
is characterized by an excavating optic nerve head. Loss of retinal ganglion cells is the
final end point in blinding diseases of the optic nerve such as glaucoma. It is known that
neuronal cell death in glaucoma occurs by ... | Hypothesis:
Subjects with pseudoexfoliation syndrome in combination with glaucoma may have an altered
activity of plasma matrix-metalloproteinase activity and a higher degree of DNA fragmentation
in the leukocytes.
Specific aims:
Determination of the level of plasma matrix-metalloproteinase activity and of t... | Inclusion Criteria:
- German native speakers
- Age between 18-80 years
- Pseudoexfoliation syndrome
- Pseudoexfoliation syndrome with open-angle glaucoma
- Primary open-angle glaucoma
Exclusion Criteria:
- Any history of ocular or systemic diseases other than glaucoma or of drug or alcohol
a... | 100 | araag2/TREC_Clinical-Trials:2023_processed:test:100 | possibly relevant | document_relevance | {
"candidate": "araag2/TREC_Clinical-Trials:2023_processed:test:patient:1__restructure_note_2",
"changes": {
"edited": [
"PT"
],
"order": null
},
"effect": "preserving",
"intent": "preserving",
"label_status": "source_label_presumed_invariant",
"mode": "restructure_note",
"side": "pati... |
araag2/TREC_Clinical-Trials:2023_processed:test:100__aug_trial_restructure_summary-permute-reword_7 | 1 | glaucoma | definitive diagnosis: primary open angle glaucoma
visual field: moderate field damage
visual acuity: 0.3
prior cataract surgery: no
prior LASIK surgery: no
comorbid ocular diseases: corneal edema | NCT00327613 | possibly relevant | Plasma Levels of Matrix Metalloproteinases (MMPs) and Degree of DNA Fragmentation in Pseudoexfoliation (PEX) Glaucoma | Plasma Levels of Matrix Metalloproteinases (MMPs) and Degree of DNA Fragmentation in Pseudoexfoliation (PEX) Glaucoma | Glaucoma is a leading global cause of blindness. This ocular neuropathy features an excavating optic nerve head. Blinding diseases of the optic nerve, including glaucoma, end with the loss of retinal ganglion cells. Apoptotic mechanisms cause neuronal cell death in glaucoma. Previous investigators showed that different... | Hypothesis:
Leukocyte DNA fragmentation may be more pronounced and plasma matrix-metalloproteinase activity altered in patients presenting with both glaucoma and pseudoexfoliation syndrome.
Specific aims:
Determination of the level of plasma matrix-metalloproteinase activity and of the degree of
DNA fragmenta... | Inclusion Criteria:
- Age between 18-80 years
- Pseudoexfoliation syndrome
- German native speakers
- Primary open-angle glaucoma
- Open-angle glaucoma associated with pseudoexfoliation syndrome
Exclusion Criteria:
- Any condition potentially interfering with the visual field results. Visual ... | 100 | araag2/TREC_Clinical-Trials:2023_processed:test:100 | possibly relevant | document_relevance | {
"candidate": "araag2/TREC_Clinical-Trials:2023_processed:test:trial:NCT00327613__restructure_summary-permute-reword_7",
"changes": {
"edited": [
"SU",
"DD.p2.s1",
"DD.p9.s3",
"DD.p9.s2",
"DD.p10.s5",
"DD.p10.s7",
"DD.p10.s2",
"DD.p11.s1",
"EL.I1.4"
],
... |
araag2/TREC_Clinical-Trials:2023_processed:test:100__aug_trial_restructure_summary-permute-reword_8 | 1 | glaucoma | definitive diagnosis: primary open angle glaucoma
visual field: moderate field damage
visual acuity: 0.3
prior cataract surgery: no
prior LASIK surgery: no
comorbid ocular diseases: corneal edema | NCT00327613 | possibly relevant | Plasma Levels of Matrix Metalloproteinases (MMPs) and Degree of DNA Fragmentation in Pseudoexfoliation (PEX) Glaucoma | Plasma Levels of Matrix Metalloproteinases (MMPs) and Degree of DNA Fragmentation in Pseudoexfoliation (PEX) Glaucoma | As a leading global cause of blindness, glaucoma is an ocular neuropathy characterized by an excavating optic nerve head, where the final end point of such optic nerve diseases is the loss of retinal ganglion cells. Because neuronal cell death in glaucoma occurs via apoptotic mechanisms, earlier studies demonstrated th... | Hypothesis:
Subjects with pseudoexfoliation syndrome in combination with glaucoma may have an altered
activity of plasma matrix-metalloproteinase activity and a higher degree of DNA fragmentation
in the leukocytes.
Specific aims:
Determination of the level of plasma matrix-metalloproteinase activity and of t... | Inclusion Criteria:
- Primary open-angle glaucoma
- Age between 18-80 years
- Open-angle glaucoma associated with pseudoexfoliation syndrome
- Native speakers of German
- Pseudoexfoliation syndrome
Exclusion Criteria:
- Any mentally impaired patient.
- Any condition potentially interferin... | 100 | araag2/TREC_Clinical-Trials:2023_processed:test:100 | possibly relevant | document_relevance | {
"candidate": "araag2/TREC_Clinical-Trials:2023_processed:test:trial:NCT00327613__restructure_summary-permute-reword_8",
"changes": {
"edited": [
"SU",
"DD.p9.s1",
"DD.p9.s4",
"DD.p10.s4",
"DD.p10.s2",
"DD.p12.s1",
"EL.I1.4",
"EL.I1.1"
],
"order": {
... |
araag2/TREC_Clinical-Trials:2023_processed:test:100__aug_trial_restructure_summary-permute-reword_3 | 1 | glaucoma | definitive diagnosis: primary open angle glaucoma
visual field: moderate field damage
visual acuity: 0.3
prior cataract surgery: no
prior LASIK surgery: no
comorbid ocular diseases: corneal edema | NCT00327613 | possibly relevant | Plasma Levels of Matrix Metalloproteinases (MMPs) and Degree of DNA Fragmentation in Pseudoexfoliation (PEX) Glaucoma | Plasma Levels of Matrix Metalloproteinases (MMPs) and Degree of DNA Fragmentation in Pseudoexfoliation (PEX) Glaucoma | Blindness is caused globally in a leading capacity by glaucoma. An excavating optic nerve head characterizes the key feature of this ocular neuropathy. In diseases of the optic nerve that lead to blindness, such as glaucoma, the final end point is the loss of retinal ganglion cells. It is established that apoptotic mec... | Hypothesis:
Subjects with pseudoexfoliation syndrome in combination with glaucoma may have an altered
activity of plasma matrix-metalloproteinase activity and a higher degree of DNA fragmentation
in the leukocytes.
Specific aims:
Comparison of plasma matrix-metalloproteinase activity levels and leukocyte DNA... | Inclusion Criteria:
- Age between 18-80 years
- Pseudoexfoliation syndrome
- German native speakers
- Pseudoexfoliation syndrome with open-angle glaucoma
- Primary open-angle glaucoma
Exclusion Criteria:
- Any condition that could potentially interfere with visual field results. Visual fields... | 100 | araag2/TREC_Clinical-Trials:2023_processed:test:100 | possibly relevant | document_relevance | {
"candidate": "araag2/TREC_Clinical-Trials:2023_processed:test:trial:NCT00327613__restructure_summary-permute-reword_3",
"changes": {
"edited": [
"SU",
"DD.p4.s1",
"DD.p6.s2",
"DD.p6.s1",
"DD.p7.s3",
"DD.p9.s4",
"DD.p10.s2",
"DD.p10.s3",
"EL.E1.2"
],
... |
araag2/TREC_Clinical-Trials:2023_processed:test:100__aug_trial_restructure_summary-permute-reword_1 | 1 | glaucoma | definitive diagnosis: primary open angle glaucoma
visual field: moderate field damage
visual acuity: 0.3
prior cataract surgery: no
prior LASIK surgery: no
comorbid ocular diseases: corneal edema | NCT00327613 | possibly relevant | Plasma Levels of Matrix Metalloproteinases (MMPs) and Degree of DNA Fragmentation in Pseudoexfoliation (PEX) Glaucoma | Plasma Levels of Matrix Metalloproteinases (MMPs) and Degree of DNA Fragmentation in Pseudoexfoliation (PEX) Glaucoma | Glaucoma is a leading cause of blindness worldwide. An excavating optic nerve head characterizes this ocular neuropathy. Blinding diseases of the optic nerve, such as glaucoma, end in the loss of retinal ganglion cells. Apoptotic mechanisms cause neuronal cell death in glaucoma. Previous investigators showed that diffe... | Hypothesis:
Subjects with pseudoexfoliation syndrome in combination with glaucoma may have an altered
activity of plasma matrix-metalloproteinase activity and a higher degree of DNA fragmentation
in the leukocytes.
Specific aims:
Determination of the level of plasma matrix-metalloproteinase activity and of t... | Inclusion Criteria:
- Primary open-angle glaucoma
- Age between 18-80 years
- Pseudoexfoliation syndrome
- German native speakers
- Open-angle glaucoma associated with pseudoexfoliation syndrome
Exclusion Criteria:
- Any condition potentially interfering with the visual field results. Visual ... | 100 | araag2/TREC_Clinical-Trials:2023_processed:test:100 | possibly relevant | document_relevance | {
"candidate": "araag2/TREC_Clinical-Trials:2023_processed:test:trial:NCT00327613__restructure_summary-permute-reword_1",
"changes": {
"edited": [
"SU",
"DD.p6.s1",
"DD.p7.s4",
"DD.p9.s3",
"DD.p10.s6",
"DD.p10.s2",
"DD.p10.s8",
"EL.I1.4"
],
"order": {
... |
araag2/TREC_Clinical-Trials:2023_processed:test:159 | 1 | glaucoma | definitive diagnosis: primary open angle glaucoma
visual field: moderate field damage
visual acuity: 0.3
prior cataract surgery: no
prior LASIK surgery: no
comorbid ocular diseases: corneal edema | NCT00444249 | not relevant | Influence of Blue Light Filtering Intraocular Lenses on Daytime Levels of Melatonin | Influence of Blue Light Filtering Intraocular Lenses on Daytime Levels of Melatonin | The "blue light hazard" has been reported to cause retinal damage (oxidative stress),
particularly to the central fovea due to its energetic, shorter wavelength visible photons,
which is why blue-light filtering intraocular lenses have been developed for cataract
surgery. The hormone melatonin has been reported to p... | Patients with non-exudative age-related macular degeneration, which are planned for cataract
surgery, will be randomized into one of four groups. Group I and II are blue light filtering
intraocular lenses and group III and IV are white lenses. Group I and III are lenses form
Alcon, group II and IV are lenses form Ho... | Inclusion Criteria:
Patients are included if they meet all of the following inclusion criteria:
- Cataract on one or both eyes
- Study eye with non-exudative AMD AREDS I - III
- Men or women aged between 60 - 99 years
- Patient planned for cataract surgery and in need of an intraocular lens
Exclus... | 159 | araag2/TREC_Clinical-Trials:2023_processed:test:159 | not relevant | document_relevance | {
"candidate": null,
"changes": null,
"effect": null,
"intent": null,
"label_status": null,
"mode": "original",
"side": null,
"summary": null,
"variant": null
} |
araag2/TREC_Clinical-Trials:2023_processed:test:159__aug_patient_restructure_note_1 | 1 | glaucoma | Current findings include a visual acuity of 0.3, moderate field damage on visual field testing, and comorbid corneal edema. The patient has a definitive diagnosis of primary open angle glaucoma and no history of LASIK surgery or cataract surgery. | NCT00444249 | not relevant | Influence of Blue Light Filtering Intraocular Lenses on Daytime Levels of Melatonin | Influence of Blue Light Filtering Intraocular Lenses on Daytime Levels of Melatonin | The "blue light hazard" has been reported to cause retinal damage (oxidative stress),
particularly to the central fovea due to its energetic, shorter wavelength visible photons,
which is why blue-light filtering intraocular lenses have been developed for cataract
surgery. The hormone melatonin has been reported to p... | Patients with non-exudative age-related macular degeneration, which are planned for cataract
surgery, will be randomized into one of four groups. Group I and II are blue light filtering
intraocular lenses and group III and IV are white lenses. Group I and III are lenses form
Alcon, group II and IV are lenses form Ho... | Inclusion Criteria:
Patients are included if they meet all of the following inclusion criteria:
- Cataract on one or both eyes
- Study eye with non-exudative AMD AREDS I - III
- Men or women aged between 60 - 99 years
- Patient planned for cataract surgery and in need of an intraocular lens
Exclus... | 159 | araag2/TREC_Clinical-Trials:2023_processed:test:159 | not relevant | document_relevance | {
"candidate": "araag2/TREC_Clinical-Trials:2023_processed:test:patient:1__restructure_note_1",
"changes": {
"edited": [
"PT"
],
"order": null
},
"effect": "preserving",
"intent": "preserving",
"label_status": "source_label_presumed_invariant",
"mode": "restructure_note",
"side": "pati... |
araag2/TREC_Clinical-Trials:2023_processed:test:159__aug_patient_restructure_note_7 | 1 | glaucoma | Diagnosis: primary open angle glaucoma. Comorbidities include corneal edema. Visual acuity is 0.3, and the visual field shows moderate damage. History is negative for cataract and LASIK surgery. | NCT00444249 | not relevant | Influence of Blue Light Filtering Intraocular Lenses on Daytime Levels of Melatonin | Influence of Blue Light Filtering Intraocular Lenses on Daytime Levels of Melatonin | The "blue light hazard" has been reported to cause retinal damage (oxidative stress),
particularly to the central fovea due to its energetic, shorter wavelength visible photons,
which is why blue-light filtering intraocular lenses have been developed for cataract
surgery. The hormone melatonin has been reported to p... | Patients with non-exudative age-related macular degeneration, which are planned for cataract
surgery, will be randomized into one of four groups. Group I and II are blue light filtering
intraocular lenses and group III and IV are white lenses. Group I and III are lenses form
Alcon, group II and IV are lenses form Ho... | Inclusion Criteria:
Patients are included if they meet all of the following inclusion criteria:
- Cataract on one or both eyes
- Study eye with non-exudative AMD AREDS I - III
- Men or women aged between 60 - 99 years
- Patient planned for cataract surgery and in need of an intraocular lens
Exclus... | 159 | araag2/TREC_Clinical-Trials:2023_processed:test:159 | not relevant | document_relevance | {
"candidate": "araag2/TREC_Clinical-Trials:2023_processed:test:patient:1__restructure_note_7",
"changes": {
"edited": [
"PT"
],
"order": null
},
"effect": "preserving",
"intent": "preserving",
"label_status": "source_label_presumed_invariant",
"mode": "restructure_note",
"side": "pati... |
araag2/TREC_Clinical-Trials:2023_processed:test:159__aug_patient_restructure_note_8 | 1 | glaucoma | The patient has primary open angle glaucoma. Visual field damage is moderate. Visual acuity is 0.3. The patient has not had cataract surgery. LASIK surgery was not performed. Corneal edema is a comorbid ocular disease. | NCT00444249 | not relevant | Influence of Blue Light Filtering Intraocular Lenses on Daytime Levels of Melatonin | Influence of Blue Light Filtering Intraocular Lenses on Daytime Levels of Melatonin | The "blue light hazard" has been reported to cause retinal damage (oxidative stress),
particularly to the central fovea due to its energetic, shorter wavelength visible photons,
which is why blue-light filtering intraocular lenses have been developed for cataract
surgery. The hormone melatonin has been reported to p... | Patients with non-exudative age-related macular degeneration, which are planned for cataract
surgery, will be randomized into one of four groups. Group I and II are blue light filtering
intraocular lenses and group III and IV are white lenses. Group I and III are lenses form
Alcon, group II and IV are lenses form Ho... | Inclusion Criteria:
Patients are included if they meet all of the following inclusion criteria:
- Cataract on one or both eyes
- Study eye with non-exudative AMD AREDS I - III
- Men or women aged between 60 - 99 years
- Patient planned for cataract surgery and in need of an intraocular lens
Exclus... | 159 | araag2/TREC_Clinical-Trials:2023_processed:test:159 | not relevant | document_relevance | {
"candidate": "araag2/TREC_Clinical-Trials:2023_processed:test:patient:1__restructure_note_8",
"changes": {
"edited": [
"PT"
],
"order": null
},
"effect": "preserving",
"intent": "preserving",
"label_status": "source_label_presumed_invariant",
"mode": "restructure_note",
"side": "pati... |
araag2/TREC_Clinical-Trials:2023_processed:test:159__aug_patient_restructure_note_2 | 1 | glaucoma | Dx: primary open angle glaucoma. Moderate visual field damage. VA 0.3. No history of cataract or LASIK surgery. Comorbid corneal edema. | NCT00444249 | not relevant | Influence of Blue Light Filtering Intraocular Lenses on Daytime Levels of Melatonin | Influence of Blue Light Filtering Intraocular Lenses on Daytime Levels of Melatonin | The "blue light hazard" has been reported to cause retinal damage (oxidative stress),
particularly to the central fovea due to its energetic, shorter wavelength visible photons,
which is why blue-light filtering intraocular lenses have been developed for cataract
surgery. The hormone melatonin has been reported to p... | Patients with non-exudative age-related macular degeneration, which are planned for cataract
surgery, will be randomized into one of four groups. Group I and II are blue light filtering
intraocular lenses and group III and IV are white lenses. Group I and III are lenses form
Alcon, group II and IV are lenses form Ho... | Inclusion Criteria:
Patients are included if they meet all of the following inclusion criteria:
- Cataract on one or both eyes
- Study eye with non-exudative AMD AREDS I - III
- Men or women aged between 60 - 99 years
- Patient planned for cataract surgery and in need of an intraocular lens
Exclus... | 159 | araag2/TREC_Clinical-Trials:2023_processed:test:159 | not relevant | document_relevance | {
"candidate": "araag2/TREC_Clinical-Trials:2023_processed:test:patient:1__restructure_note_2",
"changes": {
"edited": [
"PT"
],
"order": null
},
"effect": "preserving",
"intent": "preserving",
"label_status": "source_label_presumed_invariant",
"mode": "restructure_note",
"side": "pati... |
araag2/TREC_Clinical-Trials:2023_processed:test:159__aug_trial_restructure_summary-permute-reword_5 | 1 | glaucoma | definitive diagnosis: primary open angle glaucoma
visual field: moderate field damage
visual acuity: 0.3
prior cataract surgery: no
prior LASIK surgery: no
comorbid ocular diseases: corneal edema | NCT00444249 | not relevant | Influence of Blue Light Filtering Intraocular Lenses on Daytime Levels of Melatonin | Influence of Blue Light Filtering Intraocular Lenses on Daytime Levels of Melatonin | Due to the energetic, shorter wavelength visible photons of "blue light hazard," which are reported to cause retinal damage via oxidative stress particularly in the central fovea, blue-light filtering intraocular lenses have been developed for cataract surgery. Melatonin, a hormone reported to possess an efficient anti... | Four groups will be the result of randomization for patients with non-exudative age-related macular degeneration scheduled for cataract surgery. Vein puncture will be performed
between 8 and 10 a.m. and has to be performed at the same time for the same patient. White lenses are used in groups III and IV, whereas group... | Inclusion Criteria:
- Cataract in one or both eyes
- Non-exudative AMD (AREDS I - III) in the study eye
- Age 60 - 99 years, male or female
- Scheduled for cataract surgery and requiring an intraocular lens
Exclusion Criteria:
- Exudative AMD in the study eye
- Other than AMD, any concomitant choroidal or reti... | 159 | araag2/TREC_Clinical-Trials:2023_processed:test:159 | not relevant | document_relevance | {
"candidate": "araag2/TREC_Clinical-Trials:2023_processed:test:trial:NCT00444249__restructure_summary-permute-reword_5",
"changes": {
"edited": [
"SU",
"DD.p1.s1",
"DD.p1.s2",
"DD.p1.s3",
"DD.p1.s4",
"DD.p1.s5",
"EL.I1.1",
"EL.E1.1"
],
"order": {
"D... |
araag2/TREC_Clinical-Trials:2023_processed:test:159__aug_trial_restructure_summary-permute-reword_1 | 1 | glaucoma | definitive diagnosis: primary open angle glaucoma
visual field: moderate field damage
visual acuity: 0.3
prior cataract surgery: no
prior LASIK surgery: no
comorbid ocular diseases: corneal edema | NCT00444249 | not relevant | Influence of Blue Light Filtering Intraocular Lenses on Daytime Levels of Melatonin | Influence of Blue Light Filtering Intraocular Lenses on Daytime Levels of Melatonin | Energetic, shorter wavelength visible photons cause oxidative stress in the retina. This "blue light hazard" particularly affects the central fovea. Consequently, developers created blue-light filtering intraocular lenses for cataract surgery. Melatonin possesses an efficient antioxidant capacity. Light information fro... | Patients with non-exudative age-related macular degeneration, which are planned for cataract
surgery, will be randomized into one of four groups. Vein puncture will be performed
between 8 and 10 a.m. and has to be performed at the same time for the same patient. Lenses from Alcon are in groups I and III, while those ... | Inclusion Criteria:
- Cataract in the one or both eyes
- Non-exudative AMD AREDS I - III in the study eye
- Women or men aged 60 - 99 years
- Requirement for an intraocular lens and planned cataract surgery
Exclusion Criteria:
- Exudative AMD in the study eye
- Retinal or choroidal disorders other than AMD in ... | 159 | araag2/TREC_Clinical-Trials:2023_processed:test:159 | not relevant | document_relevance | {
"candidate": "araag2/TREC_Clinical-Trials:2023_processed:test:trial:NCT00444249__restructure_summary-permute-reword_1",
"changes": {
"edited": [
"SU",
"DD.p1.s3",
"DD.p1.s4",
"DD.p1.s5",
"DD.p1.s7",
"DD.p1.s2",
"EL.I1.1",
"EL.E1.1"
],
"order": {
"D... |
araag2/TREC_Clinical-Trials:2023_processed:test:159__aug_trial_restructure_summary-permute-reword_6 | 1 | glaucoma | definitive diagnosis: primary open angle glaucoma
visual field: moderate field damage
visual acuity: 0.3
prior cataract surgery: no
prior LASIK surgery: no
comorbid ocular diseases: corneal edema | NCT00444249 | not relevant | Influence of Blue Light Filtering Intraocular Lenses on Daytime Levels of Melatonin | Influence of Blue Light Filtering Intraocular Lenses on Daytime Levels of Melatonin | Retinal damage caused by oxidative stress has been attributed to the "blue light hazard," specifically affecting the central fovea because of energetic, shorter wavelength visible photons; consequently, blue-light filtering intraocular lenses were developed for cataract surgery. Melatonin is a hormone reported to have ... | Four groups will be the target of randomization for patients with non-exudative age-related macular degeneration who are scheduled for cataract surgery. Group I and III are lenses form
Alcon, group II and IV are lenses form Hoya. Prior to surgery, as well as at 1 month, 6 months, 1 year, and 2 years postoperatively, t... | Inclusion Criteria:
- Cataract in one or both eyes
- Non-exudative AMD (AREDS I - III) in the study eye
- Age 60 - 99 years, male or female
- Requirement for an intraocular lens and scheduled cataract surgery
Exclusion Criteria:
- Exudative AMD in the study eye
- Retinal or choroidal disorder in the study eye ... | 159 | araag2/TREC_Clinical-Trials:2023_processed:test:159 | not relevant | document_relevance | {
"candidate": "araag2/TREC_Clinical-Trials:2023_processed:test:trial:NCT00444249__restructure_summary-permute-reword_6",
"changes": {
"edited": [
"SU",
"DD.p1.s1",
"DD.p1.s4",
"DD.p1.s5",
"DD.p1.s2",
"DD.p1.s7",
"EL.I1.1",
"EL.E1.1"
],
"order": {
"D... |
araag2/TREC_Clinical-Trials:2023_processed:test:159__aug_trial_restructure_summary-permute-reword_7 | 1 | glaucoma | definitive diagnosis: primary open angle glaucoma
visual field: moderate field damage
visual acuity: 0.3
prior cataract surgery: no
prior LASIK surgery: no
comorbid ocular diseases: corneal edema | NCT00444249 | not relevant | Influence of Blue Light Filtering Intraocular Lenses on Daytime Levels of Melatonin | Influence of Blue Light Filtering Intraocular Lenses on Daytime Levels of Melatonin | Energetic, shorter wavelength visible photons cause retinal damage via oxidative stress. This effect particularly impacts the central fovea. Consequently, developers created blue-light filtering intraocular lenses for cataract surgery. Melatonin possesses an efficient antioxidant capacity. Light information travels fro... | Four groups will be the randomization destination for patients with non-exudative age-related macular degeneration scheduled for cataract surgery. Lenses from Alcon are used in groups I and III, while lenses from Hoya are used in groups II and IV. Prior to surgery, and then at 1 month, 6 months, 1 year, and 2 years pos... | Inclusion Criteria:
- Cataract in either or both eyes
- Non-exudative AMD (AREDS I - III) in the study eye
- Age 60 - 99 years, male or female
- Scheduled for cataract surgery and requiring an intraocular lens
Exclusion Criteria:
- Study eye with exudative AMD
- Concomitant retinal or choroidal disorder in the... | 159 | araag2/TREC_Clinical-Trials:2023_processed:test:159 | not relevant | document_relevance | {
"candidate": "araag2/TREC_Clinical-Trials:2023_processed:test:trial:NCT00444249__restructure_summary-permute-reword_7",
"changes": {
"edited": [
"SU",
"DD.p1.s1",
"DD.p1.s3",
"DD.p1.s4",
"DD.p1.s5",
"DD.p1.s7",
"DD.p1.s2",
"EL.I1.1",
"EL.E1.1"
],
"... |
araag2/TREC_Clinical-Trials:2023_processed:test:177 | 1 | glaucoma | definitive diagnosis: primary open angle glaucoma
visual field: moderate field damage
visual acuity: 0.3
prior cataract surgery: no
prior LASIK surgery: no
comorbid ocular diseases: corneal edema | NCT00486447 | not relevant | Perfusion Imaging and CT -Understanding Relative Efficacy | Perfusion Imaging and CT -Understanding Relative Efficacy | To determine the relative efficacy of Cardiac Computed Tomography Angiography (CCTA) and
Single Positron Emission Computed Tomography (SPECT) in patients with an intermediate risk of
CAD. | This study is a prospective, multi-center, within-subject comparative study. One hundred
fifty (150) subjects with CATH procedures are needed in the study. Approximately 300 subjects
who meet all of the inclusion/exclusion criteria will be enrolled. The study population will
consist of subjects with symptoms suspect... | Inclusion Criteria:
- Patients with an intermediate probability risk for coronary artery disease.
- Subject has symptoms of suspected ischemic heart disease.
- Subject is at intermediate risk for coronary artery disease
Exclusion Criteria:
- The subject has undergone a prior CCTA within 6 months prio... | 177 | araag2/TREC_Clinical-Trials:2023_processed:test:177 | not relevant | document_relevance | {
"candidate": null,
"changes": null,
"effect": null,
"intent": null,
"label_status": null,
"mode": "original",
"side": null,
"summary": null,
"variant": null
} |
araag2/TREC_Clinical-Trials:2023_processed:test:177__aug_patient_restructure_note_1 | 1 | glaucoma | Current findings include a visual acuity of 0.3, moderate field damage on visual field testing, and comorbid corneal edema. The patient has a definitive diagnosis of primary open angle glaucoma and no history of LASIK surgery or cataract surgery. | NCT00486447 | not relevant | Perfusion Imaging and CT -Understanding Relative Efficacy | Perfusion Imaging and CT -Understanding Relative Efficacy | To determine the relative efficacy of Cardiac Computed Tomography Angiography (CCTA) and
Single Positron Emission Computed Tomography (SPECT) in patients with an intermediate risk of
CAD. | This study is a prospective, multi-center, within-subject comparative study. One hundred
fifty (150) subjects with CATH procedures are needed in the study. Approximately 300 subjects
who meet all of the inclusion/exclusion criteria will be enrolled. The study population will
consist of subjects with symptoms suspect... | Inclusion Criteria:
- Patients with an intermediate probability risk for coronary artery disease.
- Subject has symptoms of suspected ischemic heart disease.
- Subject is at intermediate risk for coronary artery disease
Exclusion Criteria:
- The subject has undergone a prior CCTA within 6 months prio... | 177 | araag2/TREC_Clinical-Trials:2023_processed:test:177 | not relevant | document_relevance | {
"candidate": "araag2/TREC_Clinical-Trials:2023_processed:test:patient:1__restructure_note_1",
"changes": {
"edited": [
"PT"
],
"order": null
},
"effect": "preserving",
"intent": "preserving",
"label_status": "source_label_presumed_invariant",
"mode": "restructure_note",
"side": "pati... |
araag2/TREC_Clinical-Trials:2023_processed:test:177__aug_patient_restructure_note_7 | 1 | glaucoma | Diagnosis: primary open angle glaucoma. Comorbidities include corneal edema. Visual acuity is 0.3, and the visual field shows moderate damage. History is negative for cataract and LASIK surgery. | NCT00486447 | not relevant | Perfusion Imaging and CT -Understanding Relative Efficacy | Perfusion Imaging and CT -Understanding Relative Efficacy | To determine the relative efficacy of Cardiac Computed Tomography Angiography (CCTA) and
Single Positron Emission Computed Tomography (SPECT) in patients with an intermediate risk of
CAD. | This study is a prospective, multi-center, within-subject comparative study. One hundred
fifty (150) subjects with CATH procedures are needed in the study. Approximately 300 subjects
who meet all of the inclusion/exclusion criteria will be enrolled. The study population will
consist of subjects with symptoms suspect... | Inclusion Criteria:
- Patients with an intermediate probability risk for coronary artery disease.
- Subject has symptoms of suspected ischemic heart disease.
- Subject is at intermediate risk for coronary artery disease
Exclusion Criteria:
- The subject has undergone a prior CCTA within 6 months prio... | 177 | araag2/TREC_Clinical-Trials:2023_processed:test:177 | not relevant | document_relevance | {
"candidate": "araag2/TREC_Clinical-Trials:2023_processed:test:patient:1__restructure_note_7",
"changes": {
"edited": [
"PT"
],
"order": null
},
"effect": "preserving",
"intent": "preserving",
"label_status": "source_label_presumed_invariant",
"mode": "restructure_note",
"side": "pati... |
araag2/TREC_Clinical-Trials:2023_processed:test:177__aug_patient_restructure_note_8 | 1 | glaucoma | The patient has primary open angle glaucoma. Visual field damage is moderate. Visual acuity is 0.3. The patient has not had cataract surgery. LASIK surgery was not performed. Corneal edema is a comorbid ocular disease. | NCT00486447 | not relevant | Perfusion Imaging and CT -Understanding Relative Efficacy | Perfusion Imaging and CT -Understanding Relative Efficacy | To determine the relative efficacy of Cardiac Computed Tomography Angiography (CCTA) and
Single Positron Emission Computed Tomography (SPECT) in patients with an intermediate risk of
CAD. | This study is a prospective, multi-center, within-subject comparative study. One hundred
fifty (150) subjects with CATH procedures are needed in the study. Approximately 300 subjects
who meet all of the inclusion/exclusion criteria will be enrolled. The study population will
consist of subjects with symptoms suspect... | Inclusion Criteria:
- Patients with an intermediate probability risk for coronary artery disease.
- Subject has symptoms of suspected ischemic heart disease.
- Subject is at intermediate risk for coronary artery disease
Exclusion Criteria:
- The subject has undergone a prior CCTA within 6 months prio... | 177 | araag2/TREC_Clinical-Trials:2023_processed:test:177 | not relevant | document_relevance | {
"candidate": "araag2/TREC_Clinical-Trials:2023_processed:test:patient:1__restructure_note_8",
"changes": {
"edited": [
"PT"
],
"order": null
},
"effect": "preserving",
"intent": "preserving",
"label_status": "source_label_presumed_invariant",
"mode": "restructure_note",
"side": "pati... |
araag2/TREC_Clinical-Trials:2023_processed:test:177__aug_patient_restructure_note_2 | 1 | glaucoma | Dx: primary open angle glaucoma. Moderate visual field damage. VA 0.3. No history of cataract or LASIK surgery. Comorbid corneal edema. | NCT00486447 | not relevant | Perfusion Imaging and CT -Understanding Relative Efficacy | Perfusion Imaging and CT -Understanding Relative Efficacy | To determine the relative efficacy of Cardiac Computed Tomography Angiography (CCTA) and
Single Positron Emission Computed Tomography (SPECT) in patients with an intermediate risk of
CAD. | This study is a prospective, multi-center, within-subject comparative study. One hundred
fifty (150) subjects with CATH procedures are needed in the study. Approximately 300 subjects
who meet all of the inclusion/exclusion criteria will be enrolled. The study population will
consist of subjects with symptoms suspect... | Inclusion Criteria:
- Patients with an intermediate probability risk for coronary artery disease.
- Subject has symptoms of suspected ischemic heart disease.
- Subject is at intermediate risk for coronary artery disease
Exclusion Criteria:
- The subject has undergone a prior CCTA within 6 months prio... | 177 | araag2/TREC_Clinical-Trials:2023_processed:test:177 | not relevant | document_relevance | {
"candidate": "araag2/TREC_Clinical-Trials:2023_processed:test:patient:1__restructure_note_2",
"changes": {
"edited": [
"PT"
],
"order": null
},
"effect": "preserving",
"intent": "preserving",
"label_status": "source_label_presumed_invariant",
"mode": "restructure_note",
"side": "pati... |
araag2/TREC_Clinical-Trials:2023_processed:test:177__aug_trial_restructure_summary-permute-reword_8 | 1 | glaucoma | definitive diagnosis: primary open angle glaucoma
visual field: moderate field damage
visual acuity: 0.3
prior cataract surgery: no
prior LASIK surgery: no
comorbid ocular diseases: corneal edema | NCT00486447 | not relevant | Perfusion Imaging and CT -Understanding Relative Efficacy | Perfusion Imaging and CT -Understanding Relative Efficacy | To determine the relative efficacy of Single Positron Emission Computed Tomography (SPECT) compared with Cardiac Computed Tomography Angiography (CCTA) in patients presenting with an intermediate risk of CAD. | This study is a prospective, multi-center, within-subject comparative study. Approximately 300 subjects
who meet all of the inclusion/exclusion criteria will be enrolled. Subjects referred for MPS to definitively diagnose CAD, who present with symptoms suspected of and at intermediate-risk for ischemic heart disease, ... | Inclusion Criteria:
- Patients with an intermediate probability risk for coronary artery disease.
- Subject is at intermediate risk for coronary artery disease
- The subject presents with symptoms suggestive of ischemic heart disease.
Exclusion Criteria:
- Hemodynamic or active clinical instability i... | 177 | araag2/TREC_Clinical-Trials:2023_processed:test:177 | not relevant | document_relevance | {
"candidate": "araag2/TREC_Clinical-Trials:2023_processed:test:trial:NCT00486447__restructure_summary-permute-reword_8",
"changes": {
"edited": [
"SU",
"DD.p1.s4",
"DD.p3.s1",
"DD.l1.i1",
"DD.l1.i3",
"EL.I1.2",
"EL.E1.3",
"EL.E1.1",
"EL.E1.2"
],
"or... |
araag2/TREC_Clinical-Trials:2023_processed:test:177__aug_trial_restructure_summary-permute-reword_7 | 1 | glaucoma | definitive diagnosis: primary open angle glaucoma
visual field: moderate field damage
visual acuity: 0.3
prior cataract surgery: no
prior LASIK surgery: no
comorbid ocular diseases: corneal edema | NCT00486447 | not relevant | Perfusion Imaging and CT -Understanding Relative Efficacy | Perfusion Imaging and CT -Understanding Relative Efficacy | This study compares the relative efficacy of Cardiac Computed Tomography Angiography (CCTA) and Single Positron Emission Computed Tomography (SPECT). The patient population has an intermediate risk of CAD. | A prospective, multi-center, within-subject comparative design is used for this study. Approximately 300 subjects
who meet all of the inclusion/exclusion criteria will be enrolled. Subjects with symptoms suggestive of ischemic heart disease at intermediate risk, who are referred for MPS to definitively diagnose CAD, w... | Inclusion Criteria:
- Subject is at intermediate risk for coronary artery disease
- Patient presents with symptoms suggestive of ischemic heart disease.
- Patients at intermediate risk probability for coronary artery disease.
Exclusion Criteria:
- The subject has a documented history of CAD by CATH, ... | 177 | araag2/TREC_Clinical-Trials:2023_processed:test:177 | not relevant | document_relevance | {
"candidate": "araag2/TREC_Clinical-Trials:2023_processed:test:trial:NCT00486447__restructure_summary-permute-reword_7",
"changes": {
"edited": [
"SU",
"DD.p1.s1",
"DD.p1.s4",
"DD.p1.s2",
"DD.p3.s2",
"DD.p3.s1",
"DD.l1.i2",
"EL.I1.2",
"EL.I1.1"
],
"... |
araag2/TREC_Clinical-Trials:2023_processed:test:177__aug_trial_restructure_summary-permute-reword_4 | 1 | glaucoma | definitive diagnosis: primary open angle glaucoma
visual field: moderate field damage
visual acuity: 0.3
prior cataract surgery: no
prior LASIK surgery: no
comorbid ocular diseases: corneal edema | NCT00486447 | not relevant | Perfusion Imaging and CT -Understanding Relative Efficacy | Perfusion Imaging and CT -Understanding Relative Efficacy | This study compares the relative efficacy of Cardiac Computed Tomography Angiography (CCTA) and Single Positron Emission Computed Tomography (SPECT). The patient population has an intermediate risk of CAD. | This study is a prospective, multi-center, within-subject comparative study. Approximately 300 subjects
who meet all of the inclusion/exclusion criteria will be enrolled. One hundred
fifty (150) subjects with CATH procedures are needed in the study. Subjects with symptoms suggestive of ischemic heart disease at inter... | Inclusion Criteria:
- The subject presents with symptoms suggestive of ischemic heart disease.
- Patients at intermediate risk for coronary artery disease.
- Subject is at intermediate risk for coronary artery disease
Exclusion Criteria:
- The subject has hemodynamic or active clinical instability:
... | 177 | araag2/TREC_Clinical-Trials:2023_processed:test:177 | not relevant | document_relevance | {
"candidate": "araag2/TREC_Clinical-Trials:2023_processed:test:trial:NCT00486447__restructure_summary-permute-reword_4",
"changes": {
"edited": [
"SU",
"DD.p1.s4",
"DD.p2.s1",
"DD.p3.s2",
"DD.l1.i3",
"DD.l1.i2",
"EL.I1.2",
"EL.I1.1",
"EL.E1.2"
],
"o... |
araag2/TREC_Clinical-Trials:2023_processed:test:177__aug_trial_restructure_summary-permute-reword_1 | 1 | glaucoma | definitive diagnosis: primary open angle glaucoma
visual field: moderate field damage
visual acuity: 0.3
prior cataract surgery: no
prior LASIK surgery: no
comorbid ocular diseases: corneal edema | NCT00486447 | not relevant | Perfusion Imaging and CT -Understanding Relative Efficacy | Perfusion Imaging and CT -Understanding Relative Efficacy | This study compares the relative efficacy of Cardiac Computed Tomography Angiography (CCTA) and Single Positron Emission Computed Tomography (SPECT). The patient population has an intermediate risk of CAD. | This study is a prospective, multi-center, within-subject comparative study. The study population will
consist of subjects with symptoms suspected of and at intermediate-risk for ischemic heart
disease, which are referred for MPS for a definitive diagnosis of CAD. Roughly 300 subjects fulfilling all inclusion and exc... | Inclusion Criteria:
- Patients at intermediate risk probability for coronary artery disease.
- Subject is at intermediate risk for coronary artery disease
- Subject has symptoms of suspected ischemic heart disease.
Exclusion Criteria:
- The subject has hemodynamic or active clinical instability:
-... | 177 | araag2/TREC_Clinical-Trials:2023_processed:test:177 | not relevant | document_relevance | {
"candidate": "araag2/TREC_Clinical-Trials:2023_processed:test:trial:NCT00486447__restructure_summary-permute-reword_1",
"changes": {
"edited": [
"SU",
"DD.p1.s3",
"DD.p1.s2",
"DD.p2.s1",
"DD.p3.s2",
"DD.p3.s1",
"DD.l1.i3",
"DD.l1.i1",
"EL.I1.1"
],
... |
araag2/TREC_Clinical-Trials:2023_processed:test:230 | 1 | glaucoma | definitive diagnosis: primary open angle glaucoma
visual field: moderate field damage
visual acuity: 0.3
prior cataract surgery: no
prior LASIK surgery: no
comorbid ocular diseases: corneal edema | NCT00672048 | definitely relevant | Partnership for Glaucoma | Partnership for Glaucoma | The purpose of this study is to develop new ways of assisting patients with glaucoma and
their eye doctors in using the recommendations from practice guidelines. | Glaucoma is a leading cause of blindness and visual impairment in the United States,
particularly among disadvantaged populations. Despite the presence of therapies proven in
NEI, randomized controlled trials that can be delivered by more than 18,000 ophthalmologists
and 34,000 optometrists, almost nothing is known ... | Inclusion Criteria:
-Diagnosis of open angle glaucoma with documented visual field loss. | 230 | araag2/TREC_Clinical-Trials:2023_processed:test:230 | definitely relevant | document_relevance | {
"candidate": null,
"changes": null,
"effect": null,
"intent": null,
"label_status": null,
"mode": "original",
"side": null,
"summary": null,
"variant": null
} |
araag2/TREC_Clinical-Trials:2023_processed:test:230__aug_patient_restructure_note_1 | 1 | glaucoma | Current findings include a visual acuity of 0.3, moderate field damage on visual field testing, and comorbid corneal edema. The patient has a definitive diagnosis of primary open angle glaucoma and no history of LASIK surgery or cataract surgery. | NCT00672048 | definitely relevant | Partnership for Glaucoma | Partnership for Glaucoma | The purpose of this study is to develop new ways of assisting patients with glaucoma and
their eye doctors in using the recommendations from practice guidelines. | Glaucoma is a leading cause of blindness and visual impairment in the United States,
particularly among disadvantaged populations. Despite the presence of therapies proven in
NEI, randomized controlled trials that can be delivered by more than 18,000 ophthalmologists
and 34,000 optometrists, almost nothing is known ... | Inclusion Criteria:
-Diagnosis of open angle glaucoma with documented visual field loss. | 230 | araag2/TREC_Clinical-Trials:2023_processed:test:230 | definitely relevant | document_relevance | {
"candidate": "araag2/TREC_Clinical-Trials:2023_processed:test:patient:1__restructure_note_1",
"changes": {
"edited": [
"PT"
],
"order": null
},
"effect": "preserving",
"intent": "preserving",
"label_status": "source_label_presumed_invariant",
"mode": "restructure_note",
"side": "pati... |
araag2/TREC_Clinical-Trials:2023_processed:test:230__aug_patient_restructure_note_7 | 1 | glaucoma | Diagnosis: primary open angle glaucoma. Comorbidities include corneal edema. Visual acuity is 0.3, and the visual field shows moderate damage. History is negative for cataract and LASIK surgery. | NCT00672048 | definitely relevant | Partnership for Glaucoma | Partnership for Glaucoma | The purpose of this study is to develop new ways of assisting patients with glaucoma and
their eye doctors in using the recommendations from practice guidelines. | Glaucoma is a leading cause of blindness and visual impairment in the United States,
particularly among disadvantaged populations. Despite the presence of therapies proven in
NEI, randomized controlled trials that can be delivered by more than 18,000 ophthalmologists
and 34,000 optometrists, almost nothing is known ... | Inclusion Criteria:
-Diagnosis of open angle glaucoma with documented visual field loss. | 230 | araag2/TREC_Clinical-Trials:2023_processed:test:230 | definitely relevant | document_relevance | {
"candidate": "araag2/TREC_Clinical-Trials:2023_processed:test:patient:1__restructure_note_7",
"changes": {
"edited": [
"PT"
],
"order": null
},
"effect": "preserving",
"intent": "preserving",
"label_status": "source_label_presumed_invariant",
"mode": "restructure_note",
"side": "pati... |
araag2/TREC_Clinical-Trials:2023_processed:test:230__aug_patient_restructure_note_8 | 1 | glaucoma | The patient has primary open angle glaucoma. Visual field damage is moderate. Visual acuity is 0.3. The patient has not had cataract surgery. LASIK surgery was not performed. Corneal edema is a comorbid ocular disease. | NCT00672048 | definitely relevant | Partnership for Glaucoma | Partnership for Glaucoma | The purpose of this study is to develop new ways of assisting patients with glaucoma and
their eye doctors in using the recommendations from practice guidelines. | Glaucoma is a leading cause of blindness and visual impairment in the United States,
particularly among disadvantaged populations. Despite the presence of therapies proven in
NEI, randomized controlled trials that can be delivered by more than 18,000 ophthalmologists
and 34,000 optometrists, almost nothing is known ... | Inclusion Criteria:
-Diagnosis of open angle glaucoma with documented visual field loss. | 230 | araag2/TREC_Clinical-Trials:2023_processed:test:230 | definitely relevant | document_relevance | {
"candidate": "araag2/TREC_Clinical-Trials:2023_processed:test:patient:1__restructure_note_8",
"changes": {
"edited": [
"PT"
],
"order": null
},
"effect": "preserving",
"intent": "preserving",
"label_status": "source_label_presumed_invariant",
"mode": "restructure_note",
"side": "pati... |
araag2/TREC_Clinical-Trials:2023_processed:test:230__aug_patient_restructure_note_2 | 1 | glaucoma | Dx: primary open angle glaucoma. Moderate visual field damage. VA 0.3. No history of cataract or LASIK surgery. Comorbid corneal edema. | NCT00672048 | definitely relevant | Partnership for Glaucoma | Partnership for Glaucoma | The purpose of this study is to develop new ways of assisting patients with glaucoma and
their eye doctors in using the recommendations from practice guidelines. | Glaucoma is a leading cause of blindness and visual impairment in the United States,
particularly among disadvantaged populations. Despite the presence of therapies proven in
NEI, randomized controlled trials that can be delivered by more than 18,000 ophthalmologists
and 34,000 optometrists, almost nothing is known ... | Inclusion Criteria:
-Diagnosis of open angle glaucoma with documented visual field loss. | 230 | araag2/TREC_Clinical-Trials:2023_processed:test:230 | definitely relevant | document_relevance | {
"candidate": "araag2/TREC_Clinical-Trials:2023_processed:test:patient:1__restructure_note_2",
"changes": {
"edited": [
"PT"
],
"order": null
},
"effect": "preserving",
"intent": "preserving",
"label_status": "source_label_presumed_invariant",
"mode": "restructure_note",
"side": "pati... |
araag2/TREC_Clinical-Trials:2023_processed:test:230__aug_trial_restructure_summary-permute-reword_2 | 1 | glaucoma | definitive diagnosis: primary open angle glaucoma
visual field: moderate field damage
visual acuity: 0.3
prior cataract surgery: no
prior LASIK surgery: no
comorbid ocular diseases: corneal edema | NCT00672048 | definitely relevant | Partnership for Glaucoma | Partnership for Glaucoma | This study aims to develop new methods for assisting eye doctors and their glaucoma patients in the application of practice guideline recommendations. | In the United States, glaucoma is a primary driver of visual impairment and blindness, especially within disadvantaged groups. As the population of glaucoma patients is projected to more than double over the coming twenty years, while the supply of eye care providers is expected to increase by no more than 15%, strateg... | Inclusion Criteria:
Documented visual field loss and a diagnosis of open angle glaucoma. | 230 | araag2/TREC_Clinical-Trials:2023_processed:test:230 | definitely relevant | document_relevance | {
"candidate": "araag2/TREC_Clinical-Trials:2023_processed:test:trial:NCT00672048__restructure_summary-permute-reword_2",
"changes": {
"edited": [
"SU",
"DD.p1.s1",
"DD.p1.s3",
"DD.p1.s2",
"DD.p2.s2",
"DD.p2.s1",
"EL.I1.1"
],
"order": {
"DD.l1": null,
... |
araag2/TREC_Clinical-Trials:2023_processed:test:230__aug_trial_restructure_summary-permute-reword_1 | 1 | glaucoma | definitive diagnosis: primary open angle glaucoma
visual field: moderate field damage
visual acuity: 0.3
prior cataract surgery: no
prior LASIK surgery: no
comorbid ocular diseases: corneal edema | NCT00672048 | definitely relevant | Partnership for Glaucoma | Partnership for Glaucoma | This study aims to develop new methods. These methods will help glaucoma patients and their ophthalmologists use practice guideline recommendations. | In the United States, glaucoma is a primary cause of visual impairment and blindness, especially within disadvantaged populations. As the number of individuals with glaucoma is projected to more than double over the coming twenty years, while the supply of eye care providers is expected to increase by no more than 15%,... | Inclusion Criteria:
Documented visual field loss associated with a diagnosis of open angle glaucoma. | 230 | araag2/TREC_Clinical-Trials:2023_processed:test:230 | definitely relevant | document_relevance | {
"candidate": "araag2/TREC_Clinical-Trials:2023_processed:test:trial:NCT00672048__restructure_summary-permute-reword_1",
"changes": {
"edited": [
"SU",
"DD.p1.s1",
"DD.p1.s3",
"DD.p1.s2",
"DD.p2.s2",
"DD.p2.s1",
"EL.I1.1"
],
"order": {
"DD.l1": null,
... |
araag2/TREC_Clinical-Trials:2023_processed:test:230__aug_trial_restructure_summary-permute-reword_3 | 1 | glaucoma | definitive diagnosis: primary open angle glaucoma
visual field: moderate field damage
visual acuity: 0.3
prior cataract surgery: no
prior LASIK surgery: no
comorbid ocular diseases: corneal edema | NCT00672048 | definitely relevant | Partnership for Glaucoma | Partnership for Glaucoma | This study aims to create new methods for helping patients with glaucoma and their ophthalmologists implement practice guideline recommendations. | In the United States, glaucoma is a primary cause of visual impairment and blindness, especially within disadvantaged populations. As the number of individuals with glaucoma is projected to more than double over the coming twenty years, while the supply of eye care providers is expected to increase by no more than 15%,... | Inclusion Criteria:
Documented visual field loss and a diagnosis of open angle glaucoma. | 230 | araag2/TREC_Clinical-Trials:2023_processed:test:230 | definitely relevant | document_relevance | {
"candidate": "araag2/TREC_Clinical-Trials:2023_processed:test:trial:NCT00672048__restructure_summary-permute-reword_3",
"changes": {
"edited": [
"SU",
"DD.p1.s1",
"DD.p1.s3",
"DD.p1.s2",
"DD.p2.s2",
"DD.p2.s1",
"EL.I1.1"
],
"order": {
"DD.l1": null,
... |
araag2/TREC_Clinical-Trials:2023_processed:test:244 | 1 | glaucoma | definitive diagnosis: primary open angle glaucoma
visual field: moderate field damage
visual acuity: 0.3
prior cataract surgery: no
prior LASIK surgery: no
comorbid ocular diseases: corneal edema | NCT00697489 | not relevant | Treatment of Urinary Stress Incontinence During or Following Correction of Pelvic Organ Prolapse | Treatment of Urinary Stress Incontinence During or Following Correction of Pelvic Organ Prolapse | The incidence of pelvic organ prolapse (POP) in parous women is estimated over 50%. A variety
of urinary, bowel and sexual symptoms may be associated with POP. Moreover, a proportion of
women who underwent a surgical correction of POP may occur post-surgical urinary incontinence
and, thus, if this last presents as g... | Women with POP not associated to urinary stress incontinence will be enrolled and randomized
in two arms(groups A and B). Patients of group A will be treated with unique surgery
(correction of POP plus preventive continence procedure), whereas in patients of group B POP
will be surgically corrected and, in case of s... | Inclusion Criteria:
- Pelvic organ prolapse stage 2-3
- Absence of subjective urinary stress incontinence
Exclusion Criteria:
- pregnancy
- <12 months postpartum
- systemic disease known to affect bladder function
- current chemotherapy or radiation therapy
- urethral diverticulum, augmen... | 244 | araag2/TREC_Clinical-Trials:2023_processed:test:244 | not relevant | document_relevance | {
"candidate": null,
"changes": null,
"effect": null,
"intent": null,
"label_status": null,
"mode": "original",
"side": null,
"summary": null,
"variant": null
} |
araag2/TREC_Clinical-Trials:2023_processed:test:244__aug_patient_restructure_note_1 | 1 | glaucoma | Current findings include a visual acuity of 0.3, moderate field damage on visual field testing, and comorbid corneal edema. The patient has a definitive diagnosis of primary open angle glaucoma and no history of LASIK surgery or cataract surgery. | NCT00697489 | not relevant | Treatment of Urinary Stress Incontinence During or Following Correction of Pelvic Organ Prolapse | Treatment of Urinary Stress Incontinence During or Following Correction of Pelvic Organ Prolapse | The incidence of pelvic organ prolapse (POP) in parous women is estimated over 50%. A variety
of urinary, bowel and sexual symptoms may be associated with POP. Moreover, a proportion of
women who underwent a surgical correction of POP may occur post-surgical urinary incontinence
and, thus, if this last presents as g... | Women with POP not associated to urinary stress incontinence will be enrolled and randomized
in two arms(groups A and B). Patients of group A will be treated with unique surgery
(correction of POP plus preventive continence procedure), whereas in patients of group B POP
will be surgically corrected and, in case of s... | Inclusion Criteria:
- Pelvic organ prolapse stage 2-3
- Absence of subjective urinary stress incontinence
Exclusion Criteria:
- pregnancy
- <12 months postpartum
- systemic disease known to affect bladder function
- current chemotherapy or radiation therapy
- urethral diverticulum, augmen... | 244 | araag2/TREC_Clinical-Trials:2023_processed:test:244 | not relevant | document_relevance | {
"candidate": "araag2/TREC_Clinical-Trials:2023_processed:test:patient:1__restructure_note_1",
"changes": {
"edited": [
"PT"
],
"order": null
},
"effect": "preserving",
"intent": "preserving",
"label_status": "source_label_presumed_invariant",
"mode": "restructure_note",
"side": "pati... |
araag2/TREC_Clinical-Trials:2023_processed:test:244__aug_patient_restructure_note_7 | 1 | glaucoma | Diagnosis: primary open angle glaucoma. Comorbidities include corneal edema. Visual acuity is 0.3, and the visual field shows moderate damage. History is negative for cataract and LASIK surgery. | NCT00697489 | not relevant | Treatment of Urinary Stress Incontinence During or Following Correction of Pelvic Organ Prolapse | Treatment of Urinary Stress Incontinence During or Following Correction of Pelvic Organ Prolapse | The incidence of pelvic organ prolapse (POP) in parous women is estimated over 50%. A variety
of urinary, bowel and sexual symptoms may be associated with POP. Moreover, a proportion of
women who underwent a surgical correction of POP may occur post-surgical urinary incontinence
and, thus, if this last presents as g... | Women with POP not associated to urinary stress incontinence will be enrolled and randomized
in two arms(groups A and B). Patients of group A will be treated with unique surgery
(correction of POP plus preventive continence procedure), whereas in patients of group B POP
will be surgically corrected and, in case of s... | Inclusion Criteria:
- Pelvic organ prolapse stage 2-3
- Absence of subjective urinary stress incontinence
Exclusion Criteria:
- pregnancy
- <12 months postpartum
- systemic disease known to affect bladder function
- current chemotherapy or radiation therapy
- urethral diverticulum, augmen... | 244 | araag2/TREC_Clinical-Trials:2023_processed:test:244 | not relevant | document_relevance | {
"candidate": "araag2/TREC_Clinical-Trials:2023_processed:test:patient:1__restructure_note_7",
"changes": {
"edited": [
"PT"
],
"order": null
},
"effect": "preserving",
"intent": "preserving",
"label_status": "source_label_presumed_invariant",
"mode": "restructure_note",
"side": "pati... |
araag2/TREC_Clinical-Trials:2023_processed:test:244__aug_patient_restructure_note_8 | 1 | glaucoma | The patient has primary open angle glaucoma. Visual field damage is moderate. Visual acuity is 0.3. The patient has not had cataract surgery. LASIK surgery was not performed. Corneal edema is a comorbid ocular disease. | NCT00697489 | not relevant | Treatment of Urinary Stress Incontinence During or Following Correction of Pelvic Organ Prolapse | Treatment of Urinary Stress Incontinence During or Following Correction of Pelvic Organ Prolapse | The incidence of pelvic organ prolapse (POP) in parous women is estimated over 50%. A variety
of urinary, bowel and sexual symptoms may be associated with POP. Moreover, a proportion of
women who underwent a surgical correction of POP may occur post-surgical urinary incontinence
and, thus, if this last presents as g... | Women with POP not associated to urinary stress incontinence will be enrolled and randomized
in two arms(groups A and B). Patients of group A will be treated with unique surgery
(correction of POP plus preventive continence procedure), whereas in patients of group B POP
will be surgically corrected and, in case of s... | Inclusion Criteria:
- Pelvic organ prolapse stage 2-3
- Absence of subjective urinary stress incontinence
Exclusion Criteria:
- pregnancy
- <12 months postpartum
- systemic disease known to affect bladder function
- current chemotherapy or radiation therapy
- urethral diverticulum, augmen... | 244 | araag2/TREC_Clinical-Trials:2023_processed:test:244 | not relevant | document_relevance | {
"candidate": "araag2/TREC_Clinical-Trials:2023_processed:test:patient:1__restructure_note_8",
"changes": {
"edited": [
"PT"
],
"order": null
},
"effect": "preserving",
"intent": "preserving",
"label_status": "source_label_presumed_invariant",
"mode": "restructure_note",
"side": "pati... |
End of preview. Expand in Data Studio
README.md exists but content is empty.
- Downloads last month
- 45